Press Release - Company Data

Antares Pharma Announces Move to the NASDAQ Stock Market
Posted 2012-06-06 00:19NAI Editing
today announced that it will voluntarily transfer its stock exchange listing from the NYSE Amex Exchange to the NASDAQ Stock Market LLC.

Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical Sales and Marketing
Posted 2012-05-15 00:19NAI Editing
today announced the appointment of LeRoux Jooste to the position of Senior Vice President of Pharmaceutical Sales and Marketing. Mr.

Antares Pharma Reports First Quarter 2012 Financial and Operating Results
Posted 2012-05-07 23:52NAI Editing
today reported financial and operating results for the first quarter ended March 31, 2012. Quarter and Recent Highlights

Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva and Pfizer
Posted 2012-04-26 00:12NAI Editing
today announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Teva, Antares’ pharmaceutical partner, that will resolve pending patent litigation

Antares and Watson Announce the Introduction of Gelnique 3%™, for the Treatment of Overactive Bladder
Posted 2012-04-26 00:09NAI Editing
and Watson Pharmaceuticals, Inc.

Antares Pharma Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
Posted 2012-03-12 01:16NAI Editing
today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

Antares Pharma Enters Licensing Agreement with Daewoong Pharmaceuticals Co. Ltd. for Oxybutynin Gel 3% in South Korea
Posted 2012-01-17 02:09NAI Editing
today announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea.

Antares Pharma Enters Licensing Agreement with Pfizer Consumer Healthcare
Posted 2011-12-20 02:39NAI Editing
today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.

Antares Pharma Announces Issuance of New U.S. Patent Covering LibiGel®
Posted 2011-11-29 00:48NAI Editing
, a pharmaceutical company focused on self-injection pharmaceutical products and topical gel-based medicines, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No.

Antares Pharma Granted New U.S. Patent Covering VIBEX(TM) Injector Technology
Posted 2011-10-04 00:12NAI Editing
announced today that U.S.